Nano Crystal Contrast Agent
- 詳細技術說明
- This technology is the creation and implementation of nanoparticle-sized versions of known computerized tomography (CT) contrast agent dyes. These compounds are produced using co-crystal technology. The inventors have developed this methodology for iopanoic acid and plan to develop it for several other existing CT contrast agents, including diatrizoic acid, iodamide, metrizoic acid and iopydol (iodinated contrast agents).
- *Abstract
-
Background:
A medical contrast medium (or contrast agent) is a substance used to enhance the contrast of structures or fluids within the body in medical imaging. These agents are most commonly associated with the enhancement of medical images of blood vessels and the gastrointestinal tract.
Contrast agents, sometimes referred to as "dyes," are used in CT, MRI, PET, SPECT and x-ray images to highlight specific areas so that the organs, blood vessels, or tissues are more visible. By increasing the visibility of all surfaces of the organ or tissue being studied, they can help the radiologist determine the presence and extent of disease or injury. Small molecule contrast agents are the standard format used for hospital imaging applications even though they have been plagued by several issues including: 1) Non-specific distribution 2) Rapid clearing by kidneys 3) Toxicity potential 4) Solubility and morphology issues and 5) Payload restrictions.
Technology Description:
This technology is the creation and implementation of nanoparticle-sized versions of known computerized tomography (CT) contrast agent dyes. These compounds are produced using co-crystal technology. The inventors have developed this methodology for iopanoic acid and plan to develop it for several other existing CT contrast agents, including diatrizoic acid, iodamide, metrizoic acid and iopydol (iodinated contrast agents).
Key Advantages:
Nanoscale version of contrast agent molecules – Expected to overcome some of the limitations associated with conventional contrast agents (such as solubility issues and payload restrictions) by allowing commercially-available imaging agents to be easily modified.
- *Licensing
- Sean KimSenior Licensing AssociateUniversity of Iowa Research FoundationPh: 319-335-4607hyeon-kim@uiowa.edu
- 國家/地區
- 美國
